MarketScreener Strategies Monte Rosa Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 21:00:00 31/08/2026 BST			5-day change	1st Jan Change
13.94 ^USD	+4.19%		+1.20%	-11.10%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI